Annual Report & Other Reports

Annual Report & Other Reports By Year: All | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018

11 Sep 2024 CGS International Equity Research – 1H2024: Healthy Pipeline of New Products
22 Aug 2024 SAC Capital’s Equity Research – 1H2024: Commendable Growth Amid Economic Headwinds
21 Aug 2024 PhillipCapital’s Equity Research – 1H2024: New Products and Wider Distribution
16 May 2024 SAC Capital’s Equity Research – 1Q2024: Robust Growth Across All Segments
15 May 2024 CGS International Equity Research: Positive Revenue Momentum in 1Q24
09 Apr 2024 Annual Report 2023
13 Mar 2024 CGS International Equity Research: FY2023 Positive on Expanding Portfolio
27 Nov 2023 CGS-CIMB Equity Research: Dented Margins in 3Q23
20 Nov 2023 SAC Capital’s Equity Research – 3Q23 Business Update
20 Oct 2023 SAC Capital’s Equity Research – Pursuing Growth Through Full Acquisition of Ardence Pharma
22 Aug 2023 PhillipCapital’s Equity Research – Year of Investment and Challenges
18 Aug 2023 Investor-One: What You Need to Know About Hyphens Pharma’s 1H2023 Financial Results
18 Aug 2023 CGS-CIMB Equity Research: A Game of Catch-Up for 2H23F
17 Aug 2023 SAC Capital’s Equity Research – Navigating Challenges Amidst Ongoing Improvements
25 May 2023 SAC Capital’s Equity Research – Beyond the Shores
16 May 2023 CGS-CIMB Singapore’s Equity Research – Hit by Supply Chain Disruptions
13 Apr 2023 CGS-CIMB Singapore’s Equity Research – DocMed Undertakes Vietnam Digital Venture
10 Apr 2023 Annual Report 2022
09 Mar 2023 PhillipCapital’s Equity Research – Assembling Multiple Growth Engines
07 Mar 2023 CGS-CIMB Singapore’s Equity Research – FY23F Sets Stage for More Investments
24 Nov 2022 CGS-CIMB Singapore’s Equity Research – Steadfast in Executing its Business Strategy
28 Aug 2022 PhillipCapital’s Equity Research – Franchise Expands with Acquisitions
18 Aug 2022 SAC Capital’s Equity Research – Growth from Organic and Acquisition
17 Aug 2022 CGS-CIMB Singapore’s Equity Research – Positioning for Next Phase of Growth
06 Jun 2022 SAC Capital’s Equity Research – Receives S$6m Fund Infusion, Digital Assets Valued at S$60m
06 Jun 2022 PhillipCapital’s Equity Research – Digital Healthcare Catalyst Emerges
31 May 2022 Sustainability Report 2021
17 May 2022 SAC Capital’s Equity Research – Sterling 1Q22 Backed by Re-Opening Tailwind
13 May 2022 CGS-CIMB Singapore’s Equity Research – Building Up the Hype
12 Apr 2022 Annual Report 2021
04 Apr 2022 KGI Securities’ Equity Research – Novem Acquisition to Boost Top and Bottom-Line Growth
16 Mar 2022 SAC Capital’s Equity Research – Moving in the Right Direction
02 Mar 2022 CGS-CIMB Singapore’s Equity Research – Quality Earnings to Come in FY22F
06 Jan 2022 CGS-CIMB Singapore’s Equity Research – On the Lookout for Growth
22 Nov 2021 PhillipCapital’s Equity Research – Speedbump in Vietnam
18 Nov 2021 SAC Capital’s Equity Research – Strategic Acquisition of Novem Group
24 Aug 2021 SAC Capital’s Equity Research – Strongest 1H Recorded
28 Jun 2021 KGI Securities’ Equity Research – A Fresh Start
17 May 2021 Sustainability Report 2020
12 Apr 2021 Annual Report 2020
17 Mar 2021 SAC Capital’s Equity Research – Growing Regional Presence
05 Mar 2021 PhillipCapital’s Equity Research – Not to Be Written Off
19 Nov 2020 SAC Capital’s Equity Research – Q3 Setback, Longer-Term Growth is Priority
16 Nov 2020 KGI Securities’ Equity Research – Short Term Speed Bump in the Pursuit of Growth
16 Nov 2020 PhillipCapital’s Equity Research – Repositioning for Growth
06 Nov 2020 KGI Securities’ Equity Research – Skin is the game
29 Sep 2020 Lim & Tan Securities’ Equity Research – Special Report
31 Aug 2020 SAC Capital’s Equity Research – Broadening Product Range and Footprints
24 Aug 2020 KGI Securities’ Equity Research – A Hair-Raising First Half
20 Aug 2020 PhillipCapital’s Equity Research – Shaking Off COVID-19 Woes with Expanded Portfolio
20 Jul 2020 PhillipCapital’s Equity Research – Building Channels to Establish Business Longevity
26 May 2020 Sustainability Report 2019
15 May 2020 RHB’s Equity Research – Numbers Improve During Pandemic; Stay BUY
08 Apr 2020 Annual Report 2019
04 Mar 2020 RHB’s Equity Research – Near-Term Outlook Uncertain Due to COVID-19; BUY Maintained
22 Nov 2019 SAC Capital’s Equity Research – 3Q2019 Results Review
20 Nov 2019 RHB’s Equity Research – Banking on Ceradan Products; Keep Buy
08 Nov 2019 SAC Capital’s Equity Research – Healthy Prospects in ASEAN
22 Oct 2019 PhillipCapital’s Equity Research – Leveraging on Trust with Doctors for Profitability
20 Aug 2019 RHB’s Equity Research – Ceradan Leading The Pack; Keep Buy
03 Jul 2019 RHB’s Equity Research – Hyphens Pharma: Undervalued and Under-Covered; Initiate BUY
31 Dec 2018 Annual Report 2018
11 May 2018 IPO Offer Document
11 Sep 2024 CGS International Equity Research – 1H2024: Healthy Pipeline of New Products
22 Aug 2024 SAC Capital’s Equity Research – 1H2024: Commendable Growth Amid Economic Headwinds
21 Aug 2024 PhillipCapital’s Equity Research – 1H2024: New Products and Wider Distribution
16 May 2024 SAC Capital’s Equity Research – 1Q2024: Robust Growth Across All Segments
15 May 2024 CGS International Equity Research: Positive Revenue Momentum in 1Q24
09 Apr 2024 Annual Report 2023
13 Mar 2024 CGS International Equity Research: FY2023 Positive on Expanding Portfolio
27 Nov 2023 CGS-CIMB Equity Research: Dented Margins in 3Q23
20 Nov 2023 SAC Capital’s Equity Research – 3Q23 Business Update
20 Oct 2023 SAC Capital’s Equity Research – Pursuing Growth Through Full Acquisition of Ardence Pharma
22 Aug 2023 PhillipCapital’s Equity Research – Year of Investment and Challenges
18 Aug 2023 Investor-One: What You Need to Know About Hyphens Pharma’s 1H2023 Financial Results
18 Aug 2023 CGS-CIMB Equity Research: A Game of Catch-Up for 2H23F
17 Aug 2023 SAC Capital’s Equity Research – Navigating Challenges Amidst Ongoing Improvements
25 May 2023 SAC Capital’s Equity Research – Beyond the Shores
16 May 2023 CGS-CIMB Singapore’s Equity Research – Hit by Supply Chain Disruptions
13 Apr 2023 CGS-CIMB Singapore’s Equity Research – DocMed Undertakes Vietnam Digital Venture
10 Apr 2023 Annual Report 2022
09 Mar 2023 PhillipCapital’s Equity Research – Assembling Multiple Growth Engines
07 Mar 2023 CGS-CIMB Singapore’s Equity Research – FY23F Sets Stage for More Investments
24 Nov 2022 CGS-CIMB Singapore’s Equity Research – Steadfast in Executing its Business Strategy
28 Aug 2022 PhillipCapital’s Equity Research – Franchise Expands with Acquisitions
18 Aug 2022 SAC Capital’s Equity Research – Growth from Organic and Acquisition
17 Aug 2022 CGS-CIMB Singapore’s Equity Research – Positioning for Next Phase of Growth
06 Jun 2022 SAC Capital’s Equity Research – Receives S$6m Fund Infusion, Digital Assets Valued at S$60m
06 Jun 2022 PhillipCapital’s Equity Research – Digital Healthcare Catalyst Emerges
31 May 2022 Sustainability Report 2021
17 May 2022 SAC Capital’s Equity Research – Sterling 1Q22 Backed by Re-Opening Tailwind
13 May 2022 CGS-CIMB Singapore’s Equity Research – Building Up the Hype
12 Apr 2022 Annual Report 2021
04 Apr 2022 KGI Securities’ Equity Research – Novem Acquisition to Boost Top and Bottom-Line Growth
16 Mar 2022 SAC Capital’s Equity Research – Moving in the Right Direction
02 Mar 2022 CGS-CIMB Singapore’s Equity Research – Quality Earnings to Come in FY22F
06 Jan 2022 CGS-CIMB Singapore’s Equity Research – On the Lookout for Growth
22 Nov 2021 PhillipCapital’s Equity Research – Speedbump in Vietnam
18 Nov 2021 SAC Capital’s Equity Research – Strategic Acquisition of Novem Group
24 Aug 2021 SAC Capital’s Equity Research – Strongest 1H Recorded
28 Jun 2021 KGI Securities’ Equity Research – A Fresh Start
17 May 2021 Sustainability Report 2020
12 Apr 2021 Annual Report 2020
17 Mar 2021 SAC Capital’s Equity Research – Growing Regional Presence
05 Mar 2021 PhillipCapital’s Equity Research – Not to Be Written Off
19 Nov 2020 SAC Capital’s Equity Research – Q3 Setback, Longer-Term Growth is Priority
16 Nov 2020 KGI Securities’ Equity Research – Short Term Speed Bump in the Pursuit of Growth
16 Nov 2020 PhillipCapital’s Equity Research – Repositioning for Growth
06 Nov 2020 KGI Securities’ Equity Research – Skin is the game
29 Sep 2020 Lim & Tan Securities’ Equity Research – Special Report
31 Aug 2020 SAC Capital’s Equity Research – Broadening Product Range and Footprints
24 Aug 2020 KGI Securities’ Equity Research – A Hair-Raising First Half
20 Aug 2020 PhillipCapital’s Equity Research – Shaking Off COVID-19 Woes with Expanded Portfolio
20 Jul 2020 PhillipCapital’s Equity Research – Building Channels to Establish Business Longevity
26 May 2020 Sustainability Report 2019
15 May 2020 RHB’s Equity Research – Numbers Improve During Pandemic; Stay BUY
08 Apr 2020 Annual Report 2019
04 Mar 2020 RHB’s Equity Research – Near-Term Outlook Uncertain Due to COVID-19; BUY Maintained
22 Nov 2019 SAC Capital’s Equity Research – 3Q2019 Results Review
20 Nov 2019 RHB’s Equity Research – Banking on Ceradan Products; Keep Buy
08 Nov 2019 SAC Capital’s Equity Research – Healthy Prospects in ASEAN
22 Oct 2019 PhillipCapital’s Equity Research – Leveraging on Trust with Doctors for Profitability
20 Aug 2019 RHB’s Equity Research – Ceradan Leading The Pack; Keep Buy
03 Jul 2019 RHB’s Equity Research – Hyphens Pharma: Undervalued and Under-Covered; Initiate BUY
31 Dec 2018 Annual Report 2018
11 May 2018 IPO Offer Document